

**Supplemental Materials for Agudelo, Kateete, Nasinghe, et al.**

**Suppl. Table 1** See attached

**Suppl. Table 2**

**Supplemental Table 2.** Primer and adaptor sequences

PCR1 primers - amplifying V4 region of 16S rRNA

V4_515F_Nextera	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTGCCAGCMGCCGCGGTAA
V4_806R_Nextera	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGACTACHVGGGTWTCTAAT

Illumina Index adaptors

Forward index	AATGATACGGGACCACCGAGATCTACACXXXXXXXXTCGTCGGCAGCGTC
Reverse index	CAAGCAGAAGACGGCATACGAGATXXXXXXXXGTCTCGTGGGCTCGG

**Suppl. Table 3**

**Supplemental Table 3.** AMR genes identified in *Enterococcus* species


Antimicrobial resistance gene	Drug class	Mechanism	Model	Reads Species
AAC(6)-II	aminoglycoside antibiotic	antibiotic inactivation	protein homolog	<i>Enterococcus</i> (chromosome)
dfpE	diaminopyrimidine antibiotic	antibiotic target protection	protein homolog	<i>Enterococcus faecalis</i> (chromosome)
efmA	fluoroquinolone antibiotic; macrolide antibiotic	antibiotic efflux	protein homolog	<i>Enterococcus faecium</i> (chromosome)
efrA	fluoroquinolone antibiotic; macrolide antibiotic; rifamycin antibiotic	antibiotic efflux	protein homolog	<i>Enterococcus faecalis</i> (chromosome)
efrB	fluoroquinolone antibiotic; macrolide antibiotic; rifamycin antibiotic	antibiotic efflux	protein homolog	<i>Enterococcus faecalis</i> (chromosome)
ErmB	lincosamide antibiotic; macrolide antibiotic; streptogramin antibiotic	antibiotic target protection	protein homolog	<i>Enterococcus faecalis</i> (chromosome or plasmid)
ErmT	lincosamide antibiotic; macrolide antibiotic; streptogramin antibiotic	antibiotic target protection	protein homolog	<i>Enterococcus faecium</i> (chromosome or plasmid)
lsaA	lincosamide antibiotic; pleuromutilin antibiotic; streptogramin antibiotic	antibiotic target protection	protein homolog	<i>Enterococcus</i> (chromosome); <i>Enterococcus faecalis</i> (chromosome)
msrC	macrolide antibiotic; streptogramin antibiotic	antibiotic target protection	protein homolog	<i>Enterococcus faecium</i> (chromosome)
tet(L)	tetracycline antibiotic	antibiotic efflux	protein homolog	<i>Enterococcus</i> (chromosome or plasmid); <i>Enterococcus faecium</i> (chromosome or plasmid)
tet(M)	tetracycline antibiotic	antibiotic target protection	protein homolog	<i>Enterococcus faecium</i> (chromosome or plasmid)
tet(U)	tetracycline antibiotic	antibiotic efflux	protein homolog	<i>Enterococcus faecium</i> (chromosome or plasmid)

## Suppl. Table 4

**Supplemental Table 4.** USA irritable bowel disease (IBD) studies used for meta-analysis of *Enterococcus* abundance.


Study name	Citation	Studies by Geography	Location	SRA
Gut microbiome structure and metabolic activity in inflammatory bowel disease	Franzosa, Eric A et al., 2019	USA_PRISM_1	USA	PRJNA400072
Short Article Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases	Ananthakrishnan, Ashwin N et al., 2017	USA_PRISM_2	USA	PRJNA384246
Gastrointestinal Surgery for Inflammatory Bowel Disease Persistently Lowers Microbiome and Metabolome Diversity	Fang, Xin et al., 2021	USA_QIITA_11546	USA	PRJEB38352
Multi-omics analyses of the ulcerative colitis gut microbiome link <i>Bacteroides vulgatus</i> proteases with disease severity	Mills, Robert H et al., 2022	USA_QIITA_11549	USA	PRJEB42151
Dietary manipulation of the gut microbiome in inflammatory bowel disease patients: Pilot study	Oleznick, Barbara et al., 2022	USA_umass	USA	PRJNA642308
Overrepresentation of Enterobacteriaceae and <i>Escherichia coli</i> is the major gut microbiome signature in Crohn's disease and ulcerative colitis; a comprehensive metagenomic analysis of IBDMDB datasets	Khorsand, Babak et al., 2022	USA_hmbp	USA	PRJNA400072

**Suppl. Fig 1**




**Supplemental Fig. 1. A.** Principal coordinate analysis (PCoA) calculated using the weighted UniFrac distance metric is shown for males and females ( $p = 0.374$ , PERMANOVA;  $p = 0.622$ , PERMDISP). The same PCoA is also plotted with point size indicating age range (**B**;  $p < 0.01$ , PERMANOVA;  $p < 0.01$ , PERMDISP) or point color indicating district of residence (**C**).

**Suppl. Fig 2.**




**Supplemental Fig. 2** Genera differentially abundant between COVID-19 cases and controls. The relative abundance of **A** *Akkermansia* species ( $p^* < 0.05$ , Kruskal-Wallis) and **B** *Romboutsia* species ( $p^{***} < 0.0005$ , Kruskal-Wallis) in positive COVID-19 individuals and asymptomatic individuals.

### Suppl. Fig. 3



**Supplemental Fig. 3** The gut microbiome of individuals with COVID-19 with antibiotic treatment is not significantly different than individuals with COVID-19 without antibiotics. Alpha diversity is shown using **A** Faith's Phylogenetic Diversity (PD) and **B** the Shannon Index ( $p = 0.544$  Faith's PD,  $p = 0.644$  Shannon) (ABX = antibiotics, not significant - NS, Kruskal-Wallis).

### Suppl. Fig. 4



**Supplemental Fig. 4** *Enterococcus* abundance plotted by referral hospital the sample was collected at.